Key Takeaways
- Merck KGaA, Darmstadt, Germany, aims to shift from episodic checkups to continuous, passive monitoring using wearable technology. This approach provides a comprehensive understanding of disease progression and enables early detection and potential prevention of disease exacerbation.
- Digital biomarkers allow for personalized therapy by predicting disease flares and optimizing treatment schedules based on individual patient needs. This can improve patient outcomes and enhance healthcare system efficiency.
- The company's digital health strategy focuses on empowering patients with real-time health insights, fostering proactive disease management. The company also prioritizes ethical management of patient data, ensuring transparency, reliability, and security.
In conversation with Merck KGaA, Darmstadt, Germany’s Emre Ozcan, head of the company’s Healthcare business sector’s Digital Health & Devices activities, and Dimitrios Georgiopoulos, its Healthcare franchise head of Neurology and Immunology, the two leaders told In Vivo how they believe digital innovation can reshape
Myasthenia gravis, a rare chronic autoimmune neuromuscular disorder, is characterized by unpredictable flares that cause debilitating symptoms such as
